Study summary · research use only
Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This paper (species not specified; a theoretical and review discussion) summarizes principles for preparing and using killed poliovirus vaccine (KPV) for control of paralytic poliomyelitis, including the case for a one- or two-dose regimen containing sufficient antigen mass for each of the three poliovirus antigenic types to induce humoral antibody or immunologic memory after the first dose. Studies from West African and Scandinavian countries are summarized as suggesting such a vaccine should contain 40, 8, and 32 D-antigen units for types I, II, and III respectively. The paper states that if D-antigen unit measurement guides KPV standardization, manufacturing details matter, and references the Rijks Instituut voor de Volksgezondheid method as a standard for vaccine preparation.
Abstract
This paper contains a summary of the principles upon which the preparation and use of killed poliovirus vaccine (KPV) are based, as well as a summary of earlier and more recent work suggesting the feasibility of formulating a KPV preparation that would be fully and durably effective in a one- or two-dose regimen. The essential factor in the preparation of such a vaccine is the inclusion of a sufficient mass of the immunizing antigen, for each of the three antigenic types of poliovirus, to induce the formation of humoral antibody and/or immunologic memory after the first dose. The results of a series of studies carried out in West African and Scandinavian countries are summarized, which suggest that such a vaccine should contain 40, 8, and 32 D-antigen units for types I, II and III, respectively. If the D-antigen unit measurement is to be used as a guide to KPV standardization, the details of the method of manufacture are important; in this regard, the method of vaccine preparation used at the Rijks Instituut voor de Volksgezondheid should serve as a reference standard for the preparation of vaccines expected to produce the effects described.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.